Form D · Biotechnology
Gelesis Inc
Boston, MA · CIK 0001385374
Offering snapshot reported Dec 30, 2015 · SEC filing
- Reported sold
- $31.5M Offering amount: $34M
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 17, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 30, 2015 | Initial | $31,499,980 | No comparison | 6 | SEC filing |
| Jun 9, 2011 | Initial | $2,555,000 | No comparison | 11 | SEC filing |
| May 12, 2011 | Initial | $3,638,696 | No comparison | 19 | SEC filing |
| Jan 22, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Dec 26, 2006 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06c
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-254182
Source: Form D, filed Dec 30, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Mendy Axelrad | Director |
| Elon Boms | Director |
| Eric Elenko | Director |
| Meghan Fitzgerald | Director |
| Robert Forrester | Director |
| Rishi Gupta | Director |
| John Lamattina | Director |
| John La Mattina | Director |
| Elliot Maltz | Executive |
| Yishai Zohar | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
501 Boylston Street, Suite 6102
Boston, MA, 02116
Boston, MA, 02116